Abstract:Background Alzheimer's disease and related dementias (ADRD) and Parkinson's disease (PD) are the most common neurodegenerative conditions. These central nervous system disorders impact both the structure and function of the brain and may lead to imaging changes that precede symptoms. Patients with ADRD or PD have long asymptomatic phases that exhibit significant heterogeneity. Hence, quantitative measures that can provide early disease indicators are necessary to improve patient stratification, clinical care, and clinical trial design. This work uses machine learning techniques to derive such a quantitative marker from T1-weighted (T1w) brain Magnetic resonance imaging (MRI). Methods In this retrospective study, we developed machine learning (ML) based disease-specific scores based on T1w brain MRI utilizing Parkinson's Disease Progression Marker Initiative (PPMI) and Alzheimer's Disease Neuroimaging Initiative (ADNI) cohorts. We evaluated the potential of ML-based scores for early diagnosis, prognosis, and monitoring of ADRD and PD in an independent large-scale population-based longitudinal cohort, UK Biobank. Findings 1,826 dementia images from 731 participants, 3,161 healthy control images from 925 participants from the ADNI cohort, 684 PD images from 319 participants, and 232 healthy control images from 145 participants from the PPMI cohort were used to train machine learning models. The classification performance is 0.94 [95% CI: 0.93-0.96] area under the ROC Curve (AUC) for ADRD detection and 0.63 [95% CI: 0.57-0.71] for PD detection using 790 extracted structural brain features. The most predictive regions include the hippocampus and temporal brain regions in ADRD and the substantia nigra in PD. The normalized ML model's probabilistic output (ADRD and PD imaging scores) was evaluated on 42,835 participants with imaging data from the UK Biobank. There are 66 cases for ADRD and 40 PD cases whose T1 brain MRI is available during pre-diagnostic phases. For diagnosis occurrence events within 5 years, the integrated survival model achieves a time-dependent AUC of 0.86 [95% CI: 0.80-0.92] for dementia and 0.89 [95% CI: 0.85-0.94] for PD. ADRD imaging score is strongly associated with dementia-free survival (hazard ratio (HR) 1.76 [95% CI: 1.50-2.05] per S.D. of imaging score), and PD imaging score shows association with PD-free survival (hazard ratio 2.33 [95% CI: 1.55-3.50]) in our integrated model. HR and prevalence increased stepwise over imaging score quartiles for PD, demonstrating heterogeneity. As a proxy for diagnosis, we validated AD/PD polygenic risk scores of 42,835 subjects against the imaging scores, showing a highly significant association after adjusting for covariates. In both the PPMI and ADNI cohorts, the scores are associated with clinical assessments, including the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), and pathological markers, which include amyloid and tau. Finally, imaging scores are associated with polygenic risk scores for multiple diseases. Our results suggest that we can use imaging scores to assess the genetic architecture of such disorders in the future. Interpretation Our study demonstrates the use of quantitative markers generated using machine learning techniques for ADRD and PD. We show that disease probability scores obtained from brain structural features are useful for early detection, prognosis prediction, and monitoring disease progression. To facilitate community engagement and external tests of model utility, an interactive app to explore summary level data from this study and dive into external data can be found here https://ndds-brainimaging-ml.streamlit.app. As far as we know, this is the first publicly available cloud-based MRI prediction application. Funding US National Institute on Aging, and US National Institutes of Health.

Cocaine Use Prediction with Tensor-based Machine Learning on Multimodal MRI Connectome Data

Machine Learning Analysis of Cocaine Addiction Informed by DAT, SERT, and NET-Based Interactome Networks

Machine Learning of Functional Connectivity to Biotype Alcohol and Nicotine Use Disorders

Large-Scale Extended Granger Causality for Classification of Marijuana Users From Functional MRI

A brainnetome atlas-based methamphetamine dependence identification using neighborhood component analysis and machine learning on functional MRI data

Distinct neural networks predict cocaine versus cannabis treatment outcomes

Utilizing deep learning and graph mining to identify drug use on Twitter data

Predicting MCI to AD Conversation Using Integrated sMRI and rs-fMRI: Machine Learning and Graph Theory Approach

Machine-learning based prediction of future outcome using multimodal MRI during early childhood

Artificial intelligence-based analysis of behavior and brain images in cocaine-self-administered marmosets

Machine learning with neuroimaging biomarkers: Application in the diagnosis and prediction of drug addiction

Evaluating the Predictive Power of Multivariate Tensor-based Morphometry in Alzheimers Disease Progression via Convex Fused Sparse Group Lasso.

Proteome-informed machine learning studies of cocaine addiction

Prediction, prognosis and monitoring of neurodegeneration at biobank-scale via machine learning and imaging

Optimized Naive-Bayes and Decision Tree Approaches for fMRI Smoking Cessation Classification

P3‐185: Prediction of MCI to Alzheimer's Conversion Based on Tensor‐based Morphometry and Kernel Support Vector Machine

MRI-based machine learning model: A potential modality for predicting cognitive dysfunction in patients with type 2 diabetes mellitus

Abnormal resting-state functional connectome in methamphetamine-dependent patients and its application in machine-learning-based classification

Reduced Interhemispheric Resting State Functional Connectivity in Cocaine Addiction.

Diagnosis of Schizophrenia and its Subtypes Using MRI and Machine Learning

Structural and functional pathology in cocaine use disorder with polysubstance use: A multimodal fusion approach structural-functional pathology in cocaine use disorder